We aim at enabling better and ethical drug releases, without involving unnecessary animal testing.
CTL-MAT LLC is a member of the Cellular Technology Limited group that has a 20-year track record of excellence in in-vitro immune monitoring.
CTL’s founding scientists were the first to introduce protocols for functionality loss free cryopreservation of PBMC
(see our publication), as required for MAT.
CTL’s founder and CEO, Prof. Paul V. Lehmann is co-founder of CTL-MAT and acts as it’s Chief Scientific Officer.
CTL has since been the leading provider of cryopreserved PBMC, worldwide.
CTL also pioneered in vitro cytokine detection, as required for MAT testing
(see our patent) providing such test kits internationally.
CTL-MAT combines CTL’s background in immune monitoring with 15 years of leading MAT-specific expertise of Drs. Shabnam Solati,
CTL-MAT’s co-founder and CEO (see her milestone publication on MAT).